CD274 and neoplasm: 3) Among 29 patients with advanced NSCLC who developed after anti PD-1/L1 treatment, 2 patients achieved PR using pepinemab (SEMA4D inhibitor) combined with avelumab (PD-L1 inhibitor), with tumor reduction of 65.0% and 52.0%, respectively.